<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898274</url>
  </required_header>
  <id_info>
    <org_study_id>CASE11807</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE11807</secondary_id>
    <nct_id>NCT00898274</nct_id>
  </id_info>
  <brief_title>Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants</brief_title>
  <official_title>Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from patients who are at high risk of&#xD;
      developing prostate cancer may help doctors identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is looking at blood samples from patients at high risk of&#xD;
      developing prostate cancer and from healthy male participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine whether there are any changes in pro-oxidant-antioxidant profiles in&#xD;
           patients who are at high risk for developing prostate cancer.&#xD;
&#xD;
        -  To compare the profiles of these patients with those of healthy controls.&#xD;
&#xD;
      OUTLINE: Participants undergo blood sample collection. Samples are used to measure levels of&#xD;
      antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase,&#xD;
      superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA&#xD;
      damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and&#xD;
      8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and&#xD;
      enzyme-linked immunosorbent assay.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 participants (20 at high risk for developing prostate cancer&#xD;
      and 20 healthy controls) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of antioxidant enzymes as assessed by antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay</measure>
    <time_frame>at time of study entry</time_frame>
    <description>Blood (5ml) will be drawn from subjects for use in the various assays.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative DNA damage as assessed by antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay</measure>
    <time_frame>at time of study entry</time_frame>
    <description>Blood (5ml) will be drawn from subjects for use in the various assays.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Precancerous Condition</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High risk for developing prostate cancer</arm_group_label>
    <description>Male subjects age 45-65 at high risk for developing prostate cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participants</arm_group_label>
    <description>Aged matched healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <description>Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.</description>
    <arm_group_label>Healthy participants</arm_group_label>
    <arm_group_label>High risk for developing prostate cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.</description>
    <arm_group_label>Healthy participants</arm_group_label>
    <arm_group_label>High risk for developing prostate cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples from patients at high risk of developing prostate cancer and from healthy male&#xD;
      participants.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Patient at high risk for developing prostate cancer, due to 1 of the following&#xD;
                  risk factors:&#xD;
&#xD;
                    -  Histologically confirmed proliferative inflammatory atrophy and/or&#xD;
                       high-grade prostatic intraepithelial neoplasia lesions accompanied by&#xD;
                       chronic intraprostatic inflammation&#xD;
&#xD;
                    -  Abnormality observed during digital rectal exam or transrectal&#xD;
                       ultrasonography&#xD;
&#xD;
                    -  Continued elevated age-adjusted prostate-specific antigen (PSA) meeting at&#xD;
                       least 1 of the following criteria:&#xD;
&#xD;
                         -  Screening PSA &gt; 4.0 ng/mL&#xD;
&#xD;
                         -  Free PSA &lt; 18%&#xD;
&#xD;
                         -  PSA velocity &gt; 0.75 ng/mL within the past year&#xD;
&#xD;
               -  Healthy volunteer meeting the following criteria:&#xD;
&#xD;
                    -  Age-matched&#xD;
&#xD;
                    -  Normal PSA level (â‰¤ 2.1 ng/mL)&#xD;
&#xD;
                    -  Normal digital rectal exam&#xD;
&#xD;
                    -  No prostatitis or benign prostate hyperplasia&#xD;
&#xD;
                    -  No urinary symptoms (diagnosed or undiagnosed)&#xD;
&#xD;
          -  No diagnosis of cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Patients and healthy controls:&#xD;
&#xD;
          -  No chronic inflammatory conditions, especially those for which regular use of&#xD;
             non-steroidal anti-inflammatory medications (NSAIDs) is prescribed/recommended,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Coronary heart disease&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
               -  Psoriasis&#xD;
&#xD;
               -  Pelvic inflammatory disease&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Arthritis&#xD;
&#xD;
               -  Lupus&#xD;
&#xD;
               -  Hashimoto thyroiditis&#xD;
&#xD;
               -  Inflammatory bowel disease (i.e., ulcerative colitis or Crohn disease)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy or surgery to the prostate (healthy controls)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Gupta, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Suburban Health Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHHS Chagrin Highlands Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>high grade prostatic intraepithelial neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

